Y-box binding protein 1 and RNase UK114 mediate monocyte chemoattractant protein 1 mRNA stability in vascular smooth muscle cells

Molecular and Cellular Biology

Volumn 32, Issue 18, 2012, Pages 3768-3775

  Dhawan, Latika ^a,b   Liu, Bin ^a   Pytlak, Allison ^a   Kulshrestha, Satyarth ^a   Blaxall, Burns C ^a   Taubman, Mark B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DNA BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RIBONUCLEASE; RNA BINDING PROTEIN; SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CYTOPLASM; HUMAN; IMMUNOPRECIPITATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; RAT; RNA STABILITY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIBODIES; CHEMOKINE CCL2; DEXAMETHASONE; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; RIBONUCLEASES; RNA INTERFERENCE; RNA STABILITY; RNA, MESSENGER; RNA, SMALL INTERFERING; Y-BOX-BINDING PROTEIN 1;

EID: 84866503560     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00846-12     Document Type: Article

References (62)

1. Aiello RJ, et al. 1999. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1518-1525.
2. Asagi K, et al. 1998. Purification, characterization and differentiationdependent expression of a perchloric acid soluble protein from rat kidney. Nephron 79:80-90.
3. Asai K, et al. 1993. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler. Thromb. 13:892-899.
4. _ mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897.
5. Ceciliani F, et al. 1996. The primary structure of UK114 tumor antigen. FEBS Lett. 393:147-150.
6. Chervu A, Moore WS, Quiñones-Baldrich WJ, Henderson T. 1989. Efficacy of corticosteroids in suppression of intimal hyperplasia. J. Vasc. Surg. 10:129-134.
7. Coles LS, et al. 2005. Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett. 579:5372-5378.
8. Dawson J, Miltz W, Mir AK, Wiessner C. 2003. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin. Ther. Targets 7:35-48.
9. Dawson TC, Kuziel WA, Osahar TA, Maeda N. 1999. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143:205-211.
10. DeVries ME, Ran L, Kelvin DJ. 1999. On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses. Semin. Immunol. 11:95-104.
11. Dhawan L, Liu B, Blaxall BC, Taubman MB. 2007. A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability. J. Biol. Chem. 282:10146-10152.
12. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. 1988. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc. Natl. Acad. Sci. U. S. A. 85:7322-7326.
13. Evdokimova V, Ovchinnikov LP, Sorensen PH. 2006. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 5:1143-1147.
14. Evdokimova V, et al. 2001. The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer. EMBO J. 20:5491-5502.
15. Fan L, Jones SN, Padden C, Shen Q, Newburger PE. 2006. Nuclease sensitive element binding protein 1 gene disruption results in early embryonic lethality. J. Cell. Biochem. 99:140-145.
16. Gosling J, et al. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773-778.
17. Gu L, et al. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2:275-281.
18. Gu L, Tseng SC, Rollins BJ. 1999. Monocyte chemoattractant protein-1. Chem. Immunol. 72:7-29.
19. Ito K, Chung KF, Adcock IM. 2006. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 117:522-543.
20. Kanouchi H, Tachibana H, Oka T, Yamada K. 2001. Recombinant expression of perchloric acid-soluble protein reduces cell proliferation. Cell. Mol. Life Sci. 58:1340-1343.
21. Kawahara RS, Deng ZW, Deuel TF. 1991. Glucocorticoids inhibit the transcriptional induction of JE, a platelet-derived growth factor-inducible gene. J. Biol. Chem. 266:13261-13266.
22. Kim JM, Yoshikawa H, Shirahige K. 2001. A member of the YER057c/ yjgf/Uk114 family links isoleucine biosynthesis and intact mitochondria maintenance in Saccharomyces cerevisiae. Genes Cells 6:507-517.
23. Kim WJ, et al. 2003. MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem. Biophys. Res. Commun. 310: 936-942.
24. Knapp AM, Ramsey JE, Wang SX, Strauch AR, Kelm RJ, Jr. 2007. Structure-function analysis of mouse Pur beta II. Conformation altering mutations disrupt single-stranded DNA and protein interactions crucial to smooth muscle alpha-actin gene repression. J. Biol. Chem. 282:35899-35909.
25. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. 2003. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25: 691-698.
26. Krohn R, et al. 2007. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 116: 1812-1820.
27. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J. 2000. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 252:1-13.
28. Liu B, Dhawan L, Blaxall BC, Taubman MB. 2010. Protein kinase Cä mediates MCP-1 mRNA stabilization in vascular smooth muscle cells. Mol. Cell. Biochem. 344:73-79.
29. MacDermott RP. 1999. Chemokines in the inflammatory bowel diseases. J. Clin. Immunol. 19:266-272.
30. Mertens PR, Harendza S, Pollock AS, Lovett DH. 1997. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J. Biol. Chem. 272:22905-22912.
31. Mertens PR, et al. 2002. Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J. Biol. Chem. 277:24875-24882.
32. Miyamasu M, et al. 1998. Glucocorticoids inhibit chemokine generation by human eosinophils. J. Allergy Clin. Immunol. 101:75-83.
33. Mizobe K, et al. 1997. Restraint stress-induced elevation of endogenous glucocorticoid suppresses migration of granulocytes and macrophages to an inflammatory locus. J. Neuroimmunol. 73:81-89.
34. Moraes KC, Quaresma AJ, Maehnss K, Kobarg J. 2003. Identification and characterization of proteins that selectively interact with isoforms of the mRNA binding protein AUF1 (hnRNP D). Biol. Chem. 384:25-37.
35. Morishita R, et al. 1999. Ribonuclease activity of rat liver perchloric acid-soluble protein, a potent inhibitor of protein synthesis. J. Biol. Chem. 274:20688-20692.
36. Natori Y, et al. 1997. Production of monocyte chemoattractant protein-1 by cultured glomerular epithelial cells: inhibition by dexamethasone. Exp. Nephrol. 5:318-322.
37. Nekrasov MP, et al. 2003. The mRNA-binding protein YB-1 (p50) prevents association of the eukaryotic initiation factor eIF4G withmRNAand inhibits protein synthesis at the initiation stage. J. Biol. Chem. 278:13936-13943.
38. Newton R. 2000. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55:603-613.
39. Norman JT, et al. 2001. The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved reg- ulatory element in the proximal promoter. J. Biol. Chem. 276:29880-29890.
40. Ohga T, et al. 1998. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 273:5997-6000.
41. Ou ZL, Nakayama K, Natori Y, Doi N, Saito T. 2001. Effective methylprednisolone dose in experimental crescentic glomerulonephritis. Am. J. Kidney Dis. 37:411-417.
42. Panzer U, Stahl RA. 1999. Chemokines and renal inflammation. Nephrologie 20:335-341.
43. Poon M, et al. 2001. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 155:371-380.
44. Poon M, Hsu WC, Bogadanov VY, Taubman MB. 1996. Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am. J. Pathol. 149:307-317.
45. Poon M, Liu B, Taubman MB. 1999. Identification of a novel dexamethasone-sensitive RNA-destabilizing region on rat monocyte chemoattractant protein 1 mRNA. Mol. Cell. Biol. 19:6471-6478.
46. Poon M, et al. 1991. In vivo and in vitro inhibition of JE gene expression by glucocorticoids. J. Biol. Chem. 266:22375-22379.
47. Pype JL, et al. 1999. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am. J. Respir. Cell Mol. Biol. 21:528-536.
48. Rhen T, Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids- new mechanisms for old drugs. N. Engl. J. Med. 353:1711-1723.
49. Rollins BJ, Walz A, Baggiolini M. 1991. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 78:1112-1116.
50. Sato N, et al. 1999. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J. Immunol. 163:5519-5525.
51. Skabkin MA, et al. 2004. Structural organization of mRNA complexes with major core mRNP protein YB-1. Nucleic Acids Res. 32:5621-5635.
52. Skalweit A, et al. 2003. Posttranscriptional control of renin synthesis: identification of proteins interacting with renin mRNA 3'-untranslated region. Circ. Res. 92:419-427.
53. Sommerville J. 1999. Activities of cold-shock domain proteins in translation control. Bioessays 21:319-325.
54. Tesch GH. 2008. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 294:F697-F701.
55. Van Put DJ, et al. 1995. Dexamethasone influences intimal thickening and vascular reactivity in the rabbit collared carotid artery. Eur. J. Pharmacol. 294:753-761.
56. Wilkinson MF, Shyu AB. 2001. Multifunctional regulatory proteins that control gene expression in both the nucleus and the cytoplasm. Bioessays 23:775-787.
57. Xia Y, Frangogiannis NG. 2007. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm. Allergy Drug Targets 6:101-107.
58. Yamamoto-Shuda Y, Nakayama K, Saito T, Natori Y. 1999. Therapeutic effect of glucocorticoid on experimental crescentic glomerulonephritis. J. Lab. Clin. Med. 134:410-418.
59. Ying S, et al. 1999. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J. Immunol. 163:6321-6329.
60. Yla-Herttuala S, et al. 1991. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 88:5252-5256.
61. Yu X, et al. 1992. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc. Natl. Acad. Sci. U. S. A. 89:6953-6957.
62. Zhang A, et al. 2005. YB-1 coordinates vascular smooth muscle alphaactin gene activation by transforming growth factor beta1 and thrombin during differentiation of human pulmonary myofibroblasts. Mol. Biol. Cell 16:4931-4940.